Yahoo Finance Who’s Bullish on Regeneron ahead of Its 1Q16 Results?
Will Impressive 1Q16 Earnings for Regeneron Be Enough?
Regeneron’s 1Q16 results
Based out of Tarrytown, New York, Regeneron Pharmaceuticals (REGN) is a leading biotechnology company. It focuses on developing innovative drugs for serious, life-threatening diseases such as cancer, eye diseases, allergies, pain, and cardiovascular diseases.
Regeneron will report its financial and operating results for 1Q16 on May 5, 2016, before the US market opens.
Among the 20 brokerage firms covering the company, the consensus 12-month target price for Regeneron is $474.7. This translates to a ~17.4% return compared to its closing price of $404.4 on April 22, 2016.
In the latest Bloomberg survey of 27 brokerage houses on April 22, 2016, 51.9% of analysts gave a “buy” rating for Regeneron, whereas 44.4% gave “hold” recommendations, and 3.7% analysts suggested that the stock should be a “sell.” These ratings have been revised downward from the earlier count, wherein 56% of analysts were recommending a “buy” and 44% were suggesting a “hold.”
Analysts on peers
According to a Bloomberg survey of 26 analysts on April 22, 2016, 50% of analysts issued a “buy” rating for Amgen (AMGN), while 46.2% rated the stock a “hold.” A “sell” rating was issued by 3.8% analysts.
According to the ratings of 25 analysts in a Bloomberg consensus dated April 22, 2016, 64% of analysts believe that Biogen (BIIB) is a “buy,” whereas 36% suggest a “hold.” None of the analysts recommended a “sell” for it.
The Bloomberg consensus of 26 analysts on April 22, 2016, indicates that 80.8% issued a “buy” rating for Celgene (CELG), and 15.4% recommended a “hold.” About 3.8% of analysts gave the stock a “sell” rating.
To mitigate the risks of investing directly in a company’s stock, you can choose to invest in funds like the iShares Nasdaq Biotechnology ETF (IBB). IBB has ~7.4% of its total holdings in Regeneron.
Now let’s look at Regeneron’s share price performance.
Browse this series on Market Realist:
